DEFA14A: NovaBay Pharmaceuticals to Sell Avenova Assets to PRN Physician Recommended Nutriceuticals for $9.5 Million

NovaBay Pharmaceuticals has entered into a definitive agreement to sell its Avenova brand and business assets to PRN Physician Recommended Nutriceuticals for $9.5 million in cash, pending stockholder approval and customary closing conditions.

Summary

• NovaBay Pharmaceuticals has agreed to sell its Avenova brand and related assets to PRN Physician Recommended Nutriceuticals for $9.5 million in cash.
• The transaction, unanimously approved by NovaBay's board, is expected to close in the fourth quarter of 2024.
• The sale is subject to customary closing conditions, including stockholder approval.
• Following the sale, NovaBay intends to pursue an orderly wind down and dissolution of the company, distributing net proceeds to stockholders.
• The purchase price is subject to adjustment based on net working capital at closing compared to a target of $800,000, with a $500,000 escrow for potential adjustments and indemnification claims.
• The agreement includes customary representations, warranties, and indemnification provisions.
• PRN will receive a $500,000 termination fee under certain circumstances, such as NovaBay accepting a superior proposal.
• NovaBay may also receive a $500,000 termination fee if PRN fails to close after all conditions are met.
• The company plans to file a proxy statement with the SEC to seek stockholder approval for the asset sale and dissolution.
• Distributions to stockholders will likely take a minimum of nine months due to Delaware court requirements.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the sale of Avenova is presented positively, it also signals the end of NovaBay as an operating entity, which could be viewed negatively by some investors. The focus on returning value to stockholders is a positive aspect.

Positives

• The sale allows NovaBay stockholders to realize the value created with the Avenova brand.
• NovaBay's management believes PRN is an ideal home for Avenova, with a commitment to ocular health and an existing network of eyecare professionals.
• The asset sale transaction has been determined by the board to be in the best interests of the company and its stockholders.
• The company intends to distribute the net proceeds from the asset sale to its stockholders after satisfying obligations.

Negatives

• The sale of the Avenova business represents substantially all of NovaBay's revenue-generating and operating assets.
• The company plans to pursue an orderly wind down and dissolution, indicating the end of NovaBay as an operating entity.
• Stockholders will have limited ability to sell or transfer their company securities after the Certificate of Dissolution is filed.
• The distribution of the company's assets will likely take a minimum of nine months, as required by Delaware courts and law.

Risks

• The transaction is subject to stockholder approval and customary closing conditions, which may not be satisfied.
• The board reserves the right to abandon the dissolution, even if approved by stockholders, if it's no longer in the best interests of the company.
• Forward-looking statements are subject to risks and uncertainties, including the company's ability to obtain stockholder approval and complete the asset sale and dissolution.
• The company's ability to continue as a going concern while the asset sale and dissolution/liquidation are in process is a risk.

Future Outlook

NovaBay plans to pursue an orderly wind down and dissolution of the company after the sale of the Avenova business, distributing net proceeds to stockholders, debt holders, warrant holders and preferred stockholder.

Management Comments

• Justin Hall, NovaBay CEO, stated that the transaction allows stockholders to more fully realize the value created with the Avenova brand.
• Justin Hall believes they have found an ideal home for Avenova with PRN, expecting the brand to continue to grow and flourish under their leadership.

Industry Context

This announcement reflects a strategic shift for NovaBay, focusing on winding down operations after selling its primary revenue-generating asset. This type of transaction is not uncommon in the pharmaceutical industry when a company decides to focus on other areas or return capital to shareholders.

Comparison to Industry Standards

• The sale of a business unit for a fixed price plus working capital adjustments is a standard practice in M&A transactions.
• The use of an escrow account to cover potential post-closing adjustments and indemnification claims is also a common mechanism to protect the buyer.
• The termination fee of $500,000 is a typical percentage of the overall deal size, designed to compensate the buyer for their expenses if the deal falls through due to specific reasons.
• Comparable companies that have undergone similar strategic shifts include those that have divested assets to focus on core competencies or return capital to shareholders.

Stakeholder Impact

• Shareholders will receive distributions from the net proceeds of the asset sale and liquidation.
• Employees of the Avenova business may be offered employment by PRN.
• Customers of Avenova can expect the product to continue to be available under PRN's ownership.
• Suppliers and other business partners of Avenova will transition to working with PRN.

Next Steps

• NovaBay will file a proxy statement with the SEC to seek stockholder approval for the asset sale and dissolution.
• The company will hold a special meeting of stockholders to vote on the asset sale and dissolution.
• If approved, the company will file a Certificate of Dissolution with the Secretary of State of Delaware.
• The company will proceed with the liquidation and distribution of assets to stakeholders.

Key Dates

Keywords

Avenova, NovaBay Pharmaceuticals, PRN Physician Recommended Nutriceuticals, Asset Sale, Dissolution, Liquidation, Stockholder Approval, Eyecare, Net Working Capital, Termination Fee